Alec­tor re­port­ed a Phase 2 fail­ure for an Ab­b­Vie-part­nered Alzheimer’s pro­gram Mon­day af­ter­noon and said it will ...

While everyone gears up for one of the busiest travel times of the year, the Alzheimer’s Foundation of America is offering ...

Shares of Alector tumbled in after-hours trading after the company said its Alzheimer drug candidate, AL002, failed to meet its phase 2 primary endpoint of slowing clinical progression of the disease.

Cassava Sciences ( SAVA) stock dropped 87% on Monday to close the day’s trading at $4.29 a shares. Cassava is a biotechnology ...

Cassava Sciences stock plummeted Monday — wiping out more than three-quarters of its value — after the company's Alzheimer's treatment failed in Phase 3 testing. Please watch the video at ...

Stocks finished higher Monday, with major indexes hitting new intraday records during the session, as the equities market continued to rally while Treasury yields fell and bitcoin retreated.

More than 1.1 million elderly people in Bangladesh are suffering from dementia, with women comprising 75 percent of patients, ...

Cassava Sciences (SAVA) shares are cratering by over 80% on Monday after the pharmaceutical company failed to meet its latest ...

As of September 30, 2024, Alector has $457.2 million in cash, cash equivalents, and investments, which the company continues to expect will provide runway through 2026. Alector plans to provide ...

Researchers have developed a new method to profile gene activity in the living human brain, offering new insights into ...

Simufilam is an investigational oral small molecule that targets the filamin A protein. In the ReThink-ALZ study (ClinicalTrials.gov Identifier: NCT04994483 ), patients with confirmed mild or moderate ...

Thanks to a partnership with Victim Services Huron Perth, the Perth County OPP detachment has successfully relaunched Project ...